NEW YORK, September 12 /CNW/ - Pfizer Inc said today that the Canadian
Federal Court in Toronto has ruled that Pfizer's patent covering a crystalline
form of atorvastatin, the active ingredient in Lipitor, would be infringed by
Ranbaxy Laboratories Limited's process for making their proposed generic
The court granted the company's application for an order preventing
Ranbaxy from launching its product until expiration of the patent (Canadian
Patent No. 2,220,018) in July 2016. Ranbaxy may seek to appeal this decision.
The court denied the company's application for a prohibition order in
connection with a second patent covering a process for making amorphous
atorvastatin (Canadian Patent No. 2,220,455), which also expires in July 2016.
For further information:
For further information: Pfizer Inc Vanessa Aristide, 212/733-3784